DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

First Posted Date: 2019-01-25

Last Posted Date: 2022-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 171808

Registration Number: NCT03817463

Locations: 🇯🇵
Gifu University, Gifu, Japan
🇩🇰
Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology, Gentofte, Denmark
🇩🇪
University of Ulm, Institute for Epidemiology and medical biometry, Ulm, Germany

and more 10 locations

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Sodium Glucose Transporter 2 inhibitor
Drug: Dipeptidyl-peptidase 4 inhibitor
Drug: Glucagon-like peptide 1 agonist

First Posted Date: 2019-01-17

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4083

Registration Number: NCT03807440

Locations: 🇷🇺
Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095, Penza, Russian Federation
🇧🇬
MC "Diamedical 2013" OOD, Center Nr.: 35902, Dimitrovgrad, Bulgaria
🇧🇬
"Medical Center-Razgrad"OOD, Center Nr.: 35910, Razgrad, Bulgaria

and more 174 locations

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: BI 730357 mixed with [C-14] BI 730357 BS

First Posted Date: 2019-01-15

Last Posted Date: 2023-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT03804671

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495,

First Posted Date: 2019-01-14

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03802331

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764122
Drug: Placebo

First Posted Date: 2019-01-07

Last Posted Date: 2023-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 76

Registration Number: NCT03794323

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Placebo

First Posted Date: 2019-01-04

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03793621

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Itraconazole

First Posted Date: 2018-12-20

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT03782987

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Phase 2

Completed

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2018-12-20

Last Posted Date: 2022-03-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT03782792

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇫🇷
HOP Robert Debré, Reims, France
🇹🇳
Hedi Chaker Hospital, Department of Dermatology, Tunisia, Tunisia

and more 34 locations

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: BI 425809 mixed with [C-14]-BI 425809

First Posted Date: 2018-12-20

Last Posted Date: 2019-03-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT03783000

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Head and Neck Neoplasms

Interventions: Drug: BI 754111
Drug: [89Zr]Zr-BI 754111
Drug: BI 754091

First Posted Date: 2018-12-19

Last Posted Date: 2021-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT03780725

Locations: 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy